Avalo Therapeutics is a clinical-stage biotechnology company focused on IL-1-based treatments for immune-mediated inflammatory diseases. Its lead product candidate, abdakibart (AVTX-009), is an anti-IL-1 monoclonal antibody currently in a Phase 2 trial (LOTUS) for hidradenitis suppurativa (HS), with topline data expected in Q2 2026. The company also holds legacy programs including quisovalimab (AVTX-002), AVTX-006, AVTX-008, and AVTX-913, for which it is exploring strategic alternatives.
Q2 FY2026 — expected 2026-09-19
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-23 | 2025-12-31 | 0001534120-26-000011 | EDGAR | 102K words |
| 2025-03-20 | 2024-12-31 | 0001628280-25-013986 | EDGAR | 87K words |
| 2024-03-29 | 2023-12-31 | 0001628280-24-013786 | EDGAR | 80K words |
| 2023-03-29 | 2022-12-31 | 0001628280-23-009630 | EDGAR | 89K words |
| 2022-03-02 | 2021-12-31 | 0001628280-22-004671 | EDGAR | — |
| 2021-03-08 | 2020-12-31 | 0001628280-21-004162 | EDGAR | — |
| 2020-03-11 | 2019-12-31 | 0001628280-20-003395 | EDGAR | — |
| 2019-03-18 | 2018-12-31 | 0001628280-19-003078 | EDGAR | — |
| 2018-04-02 | 2017-12-31 | 0001628280-18-003890 | EDGAR | — |
| 2017-03-14 | 2016-12-31 | 0001628280-17-002566 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-06 | 2026-06-30 | 0001534120-26-000049 | EDGAR | 22K words |
| 2025-11-06 | 2025-09-30 | 0001534120-25-000018 | EDGAR | 23K words |
| 2025-08-07 | 2025-06-30 | 0001628280-25-038575 | EDGAR | 22K words |
| 2025-05-12 | 2025-03-31 | 0001628280-25-024436 | EDGAR | 19K words |
| 2024-11-07 | 2024-09-30 | 0001628280-24-045965 | EDGAR | 23K words |
| 2024-08-12 | 2024-06-30 | 0001628280-24-036591 | EDGAR | 27K words |
| 2024-05-13 | 2024-03-31 | 0001628280-24-022763 | EDGAR | 20K words |
| 2023-11-09 | 2023-09-30 | 0001628280-23-038036 | EDGAR | 22K words |
| 2023-08-03 | 2023-06-30 | 0001628280-23-026990 | EDGAR | 22K words |
| 2023-05-04 | 2023-03-31 | 0001628280-23-015703 | EDGAR | 18K words |
| 2022-11-07 | 2022-09-30 | 0001628280-22-028538 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001628280-22-020866 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-06 | 0001534120-26-000048 | EDGAR | 3K words |
| 2026-03-27 | 0001534120-26-000016 | EDGAR | 1K words |
| 2026-03-23 | 0001534120-26-000010 | EDGAR | 3K words |
| 2026-01-12 | 0001534120-26-000003 | EDGAR | 3K words |
| 2025-12-02 | 0001534120-25-000022 | EDGAR | 3K words |
| 2025-11-06 | 0001534120-25-000017 | EDGAR | 3K words |
| 2025-10-29 | 0001534120-25-000013 | EDGAR | 1K words |
| 2025-10-10 | 0001534120-25-000011 | EDGAR | 3K words |
| 2025-10-01 | 0001534120-25-000009 | EDGAR | 1K words |
| 2025-09-22 | 0001534120-25-000005 | EDGAR | 1K words |
286 total filings indexed. 254 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001534120 |
| Ticker | AVTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.avalotx.com |
| Listed | 2015-11-13 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/AVTX (~200 tokens, structured JSON with cryptographic provenance)